Pages with the fewest revisions

Jump to navigation Jump to search

Showing below up to 50 results in range #11,141 to #11,190.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Niobium carbide (1 revision)
  2. Nipple (1 revision)
  3. Nirsevimab (1 revision)
  4. Nisoldipine (patient information) (1 revision)
  5. Nitazoxanide (patient information) (1 revision)
  6. Nitazoxanide contraindications (1 revision)
  7. Nitazoxanide description (1 revision)
  8. Nitazoxanide overdosage (1 revision)
  9. Niter (1 revision)
  10. Nitrate reductase test (1 revision)
  11. Nitrazoxanide (1 revision)
  12. Nitrene (1 revision)
  13. Nitrenium ion (1 revision)
  14. Nitric oxide synthase 2A (1 revision)
  15. Nitric oxide synthase 2 (inducible) (1 revision)
  16. Nitrification (1 revision)
  17. Nitrilacarb (1 revision)
  18. Nitrile (1 revision)
  19. Nitrite oxidoreductase (1 revision)
  20. Nitrobenzene (1 revision)
  21. Nitroethane (1 revision)
  22. Nitrofurantoin clinical pharmacology (1 revision)
  23. Nitrofurantoin description (1 revision)
  24. Nitrofurantoin dosage and administration (1 revision)
  25. Nitrofurantoin how supplied (1 revision)
  26. Nitrofurantoin indications and usage (1 revision)
  27. Nitrofurantoin microbiology (1 revision)
  28. Nitrofurantoin overdosage (1 revision)
  29. Nitrofurantoin overdose (1 revision)
  30. Nitrofurantoin warnings and precautions (1 revision)
  31. Nitrogen cycle (1 revision)
  32. Nitrogen mustard (1 revision)
  33. Nitroglycerin ointment (patient information) (1 revision)
  34. Nitroglycerin skin patches (patient information) (1 revision)
  35. Nitrone (1 revision)
  36. Nitrosonium (1 revision)
  37. Nitrosyl chloride (1 revision)
  38. Nitrosylsulfuric acid (1 revision)
  39. Nivolumab and relatlimab-rmbw (1 revision)
  40. Nixtamalization (1 revision)
  41. Nizatidine (patient information) (1 revision)
  42. No-reflow phenomenon CT (1 revision)
  43. No-reflow phenomenon electrocardiography (1 revision)
  44. No-reflow phenomenon epidemiology and demographics (1 revision)
  45. No-reflow phenomenon myocardial contrast echocardiography (1 revision)
  46. No-reflow phenomenon natural history, complications and prognosis (1 revision)
  47. No-reflow phenomenon prevention (1 revision)
  48. No Compromise (magazine) (1 revision)
  49. No observable adverse effect level (NOAEL) (1 revision)
  50. No smoking day (1 revision)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://www.wikidoc.org/index.php/Special:FewestRevisions"